- Home
- EDSA vs ATYR Comparison
EDSA vs ATYR Comparison
Compare EDSA & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDSA | ATYR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.5M | 54.8M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EDSA | ATYR |
|---|---|---|
| Price | $4.43 | $0.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | ★ $5.00 | $3.67 |
| AVG Volume (30 Days) | 64.7K | ★ 679.8K |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.98 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.40 |
| 52 Week High | $20.32 | $6.50 |
Technical Indicators
Market Signals| Indicator | EDSA | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 32.50 | 49.09 |
| Support Level | $1.20 | $0.46 |
| Resistance Level | $5.82 | $0.60 |
| Average True Range (ATR) | 0.65 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 8.00 | 24.55 |
Price Performance
Historical ComparisonAbout EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).